Home Biosimilar Antibodies Protein Tyrosine Kinase TAM receptors (Tyro-3,Axl,and Mertk) Emactuzumab (Anti-CSF1R / M-CSFR / CD115)
For research use only. Not for use in humans.

Emactuzumab (Anti-CSF1R / M-CSFR / CD115)

Synonyms: CSF-1-R， CD115

Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD.

Emactuzumab (Anti-CSF1R / M-CSFR / CD115)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD.
References

Product Details

CAS No. 1448221-67-7
Molecular Weight 146.94
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03768063 ACTIVE_NOT_RECRUITING Drug: Atezolizumab|Drug: Bevacizumab|Drug: Alectinib|Drug: C Cancer Hoffmann-La Roche 2019-02-28 PHASE3
NCT05417789 ACTIVE_NOT_RECRUITING Drug: Emactuzumab|Drug: Placebo TGCT SynOx Therapeutics Limited 2024-10-09 PHASE3
NCT02923739 TERMINATED Drug: Paclitaxel Fallopian Tube Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma M.D. Anderson Cancer Center 2017-05-05 PHASE2
NCT02323191 COMPLETED Drug: Atezolizumab|Drug: Emactuzumab Solid Cancers Hoffmann-La Roche 2015-01-19 PHASE1
NCT02471716 COMPLETED Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor Five Prime Therapeutics, Inc. 2015-06 PHASE1; PHASE2
NCT03369964 WITHDRAWN Drug: Atezolizumab|Drug: Emactuzumab|Drug: Obinutuzumab Lymphoma, Non-Hodgkin Hoffmann-La Roche 2018-03-14 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.